SCHEMBL2235076

SCHEMBL2235076

CN1CCN(C(=O)c2ccc(I)cc2)CC1

nearest known ligand 0.69

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
POLB P06746 3/20 0.69
HPGD P15428 7/20 0.65
ALOX15 P16050 1/20 0.65
KMT2A Q03164 3/20 0.61
MEN1 O00255 2/20 0.61
CYP1A2 P05177 1/20 0.61
CYP2D6 P10635 1/20 0.61
CYP2C19 P33261 1/20 0.61
GRM5 P41594 1/20 0.59
TSHR P16473 1/20 0.57
HRH3 Q9Y5N1 3/20 0.56
LMNA P02545 1/20 0.56
EPHX2 P34913 1/20 0.55
NPC1 O15118 1/20 0.55
L3MBTL3 Q96JM7 1/20 0.53
L3MBTL1 Q9Y468 1/20 0.53
HRH4 Q9H3N8 1/20 0.52
ALDH1A1 P00352 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1447371 0.93 KMT2A (0.72) POLBHPGDALOX15KMT2AMEN1
SCHEMBL10724841 0.90 POLB (0.81) POLBHPGDALOX15KMT2AMEN1
SCHEMBL20449050 0.85 POLB (0.86) POLBHPGDALOX15KMT2AMEN1
SCHEMBL14980308 0.83 POLB (0.72) POLBHPGDALOX15KMT2AMEN1
SCHEMBL2473996 0.83 POLB (0.71) POLBHPGDALOX15KMT2AMEN1
SCHEMBL82433 0.83 ALDH1A1 (0.72) POLBHPGDALOX15KMT2AMEN1
SCHEMBL25498355 0.83 POLB (0.71) POLBHPGDALOX15KMT2AMEN1
SCHEMBL1424016 0.82 HPGD (0.69) POLBHPGDKMT2AMEN1TSHR
SCHEMBL1424454 0.82 HPGD (0.76) HPGDKMT2AMEN1TSHRLMNA
SCHEMBL12621027 0.81 POLB (0.87) POLBHPGDALOX15KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023154282-A1 COMPOUNDS HAVING A T-STRUCTURE FORMED BY AT LEAST FOUR CYCLES FOR USE IN THE TREATMENT OF CANCER AND OTHER INDICATIONS THERAS, INC. (US) 2023-08-17 WO disclosed
US-20230110165-A1 Substituted Imidazo[4,5-c]pyridine Compounds and Compositions Thereof PROXIMAGEN LLC (US) 2023-04-13 US disclosed
US-11512082-B2 Substituted imidazo[4,5-c]pyridine compounds and compositions thereof PROXIMAGEN, LLC (US) 2022-11-29 US disclosed
WO-2022048684-A1 JNK INHIBITOR, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF 武汉朗来科技发展有限公司 2022-03-10 WO disclosed
US-10968223-B2 Imidazo[4,5-c]pyridine and pyrrolo[2,3-c]pyridine derivatives as SSAO inhibitors PROXIMAGEN, LLC (US) 2021-04-06 US disclosed
US-10968223-B2 Imidazo[4,5-c]pyridine and pyrrolo[2,3-c]pyridine derivatives as SSAO inhibitors PROXIMAGEN, LLC (US) 2021-04-06 US disclosed
EP-3145929-B1 5-CHLORO-2-DIFLUOROMETHOXYPHENYL PYRAZOLOPYRIMIDINE COMPOUNDS WHICH ARE JAK INHIBITORS HOFFMANN LA ROCHE (CH) 2021-01-13 EP disclosed
US-20200347059-A1 IMIDAZO[4,5-C]PYRIDINE AND PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS SSAO INHIBITORS PROXIMAGEN, LLC (US) 2020-11-05 US disclosed
US-20200347059-A1 IMIDAZO[4,5-C]PYRIDINE AND PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS SSAO INHIBITORS PROXIMAGEN, LLC (US) 2020-11-05 US disclosed
US-10766897-B2 Imidazo[4,5-c]pyridine and pyrrolo[2,3-c]pyridine derivatives as SSAO inhibitors PROXIMAGEN, LLC (US) 2020-09-08 US disclosed
US-20130012518-A1 BICYCLIC COMPOUNDS AND THEIR USES AS DUAL C-SRC / JAK INHIBITORS AURIGENE DISCOVERY TECHNOLOGIES LTD. (IN) 2013-01-10 US disclosed
CN-102858770-A Bicyclic Compounds And Their Uses As Dual C-src / Jak Inhibitors DEBIOPHARM SA 2013-01-02 CN disclosed
EP-2536722-A1 BICYCLIC COMPOUNDS AND THEIR USES AS DUAL C-SRC / JAK INHIBITORS Debiopharm S.A. (CH) 2012-12-26 EP disclosed
WO-2011101806-A1 BICYCLIC COMPOUNDS AND THEIR USES AS DUAL C-SRC / JAK INHIBITORS DEBIOPHARM S.A. (CH) 2011-08-25 WO disclosed
WO-2011101806-A1 BICYCLIC COMPOUNDS AND THEIR USES AS DUAL C-SRC / JAK INHIBITORS DEBIOPHARM S.A. (CH) 2011-08-25 WO disclosed
US-7494994-B2 Phenylpyridylpiperazine compounds LES LABORATOIRES SERVIER (FR) 2009-02-24 US disclosed
US-20060258670-A1 New phenylpyridylpiperazine compounds LES LABORATOIRES SERVIER (FR) 2006-11-16 US disclosed
WO-2006120349-A1 NOVEL PHENYL-PYRIDINYL-PIPERAZINE DERIVATIVES, A METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAID DERIVATIVES LES LABORATOIRES SERVIER (FR) 2006-11-16 WO disclosed
EP-1721897-A1 Phenylpyridinylpiperazin derivatives, the process to make them and the pharmaceutical compositions containing them Les Laboratoires Servier (FR) 2006-11-15 EP disclosed
US-4990505-A Treating asthma, bronchitis; adrenergic stimulants GLAXO GROUP LIMITED (GB) 1991-02-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060258670-A1 New phenylpyridylpiperazine compounds HRH4, HRH3, HRH2 POLB 4224/4885HPGD 1922/4885ALOX15 2649/4885
US-11512082-B2 Substituted imidazo[4,5-c]pyridine compounds and compositions thereof PNPO, XDH, EPX POLB 1538/4885HPGD 273/4885ALOX15 126/4885
US-10766897-B2 Imidazo[4,5-c]pyridine and pyrrolo[2,3-c]pyridine derivatives as SSAO inhibitors PNPO, SSB, XDH POLB 759/4885HPGD 1314/4885ALOX15 414/4885
US-20130012518-A1 BICYCLIC COMPOUNDS AND THEIR USES AS DUAL C-SRC / JAK INHIBITORS JAK2, SRC, JAK1 POLB 3848/4885HPGD 3915/4885ALOX15 4051/4885
US-10968223-B2 Imidazo[4,5-c]pyridine and pyrrolo[2,3-c]pyridine derivatives as SSAO inhibitors PNPO, PPOX, SCO2 POLB 1538/4885HPGD 335/4885ALOX15 401/4885
US-20230110165-A1 Substituted Imidazo[4,5-c]pyridine Compounds and Compositions Thereof PNPO, XDH, EPX POLB 1538/4885HPGD 273/4885ALOX15 126/4885
US-20200347059-A1 IMIDAZO[4,5-C]PYRIDINE AND PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS SSAO INHIBITORS PNPO, PPOX, SCO2 POLB 1538/4885HPGD 335/4885ALOX15 401/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.